Skip to content Skip to menu

New MA Chairman starts today

Monday, 4 November 2013

Media Release

 Medicines Australia announced that its new Chairman, Dr Martin Cross, is appointed from today.

“I’m delighted to be taking up this most important position for the medicines industry and the Australian community,” Dr Cross said.

“This is a critical time for the Australian medicines industry as it is facing huge challenges while also offering so much opportunity for the future.”

“We welcome Martin to the position of Chairman of Medicines Australia,” said Medicines Australia Chief Executive, Dr Brendan Shaw.

“Martin comes with a wealth of experience in the Australian medicines industry and I congratulate him on his commencement today as Chairman.”

Dr Cross was Managing Director of Alphapharm, Chair of the Generic Medicines Industry Association and Chair of the Pharmaceutical Industry Council.

He has previously been Managing Director of Novartis in Australia and a member of the Medicines Australia Board. He has also previously worked over many years for ICI, Zeneca and AstraZeneca, another Medicines Australia member company.

“I also want to thank Mr Mark Fladrich, Managing Director of AstraZeneca and MA Board member, for stepping in as Chairman before Martin’s appointment,” Dr Shaw said.

“Mark led Medicines Australia for nine months through a difficult period for the industry. His leadership has been important in setting the industry’s direction for the future.”

-ENDS-

Contact Person:

Alex Chapman
Phone: (02) 8281 3204
Email:
alex@ogilvyprhealth.com

Top